ADPT Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
Adaptive Biotechnologies Corp (ADPT) shows a mixed outlook. While the stock has experienced recent price gains and positive institutional interest, the lack of strong technical buy signals, neutral RSI, and the absence of recent congress trading data suggest that this is not an ideal entry point for a long-term, beginner investor. Additionally, the stock's short-term trend indicates potential minor declines, making it better to wait for a more favorable entry point.
The MACD is positive and contracting, indicating a bullish trend. The RSI is neutral at 58.082, and moving averages are bullish (SMA_5 > SMA_20 > SMA_200). Key support and resistance levels are at S1: 16.202 and R1: 18.971. However, the stock's short-term trend suggests a potential -2.45% decline in the next week.
Hedge funds have significantly increased their buying activity by 176.86% over the last quarter.
Strong institutional demand for the company's convertible notes offering, which was increased from $250 million to $300 million.
Bullish moving averages and recent price gains.
Insider selling by Chief People Officer Francis Lo, who sold shares worth $695,
Analysts have lowered price targets recently, with Morgan Stanley reducing the target to $18 and JPMorgan to $
Short-term stock trend indicates potential minor declines (-2.45% in the next week).
Financial data is unavailable for the latest quarter, making it difficult to assess growth trends.
Analyst ratings are mixed: Morgan Stanley maintains an Equal Weight rating with a reduced price target of $18, JPMorgan has an Overweight rating with a reduced price target of $19, and TD Cowen has a Buy rating with an increased price target of $21.
